BiotechTube

Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Staphylococcus Aureus Infection

Conditions

Staphylococcus Aureus Infection

Trial Timeline

Aug 1, 2008 → Jan 1, 2010

NCT ID
NCT00572910

About Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)

Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) is a phase 2 stage product being developed by Merck for Staphylococcus Aureus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00572910. Target conditions include Staphylococcus Aureus Infection.

What happened to similar drugs?

2 of 4 similar drugs in Staphylococcus Aureus Infection were approved

Approved (2) Terminated (0) Active (2)
🔄Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3
✅Imipenem/cilastatinPfizerApproved
✅linezolid (Zyvox) + vancomycinPfizerApproved
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00572910Phase 2Completed

Competing Products

12 competing products in Staphylococcus Aureus Infection

See all competitors
ProductCompanyStageHype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3
40
AZD7760AstraZenecaPhase 1/2
39
V710 + PlaceboMerckPhase 2/3
30
DaptomycinMerckPhase 2
35
Imipenem/cilastatinPfizerApproved
39
linezolid (Zyvox) + vancomycinPfizerApproved
43
Linezolid + VancomycinPfizerPre-clinical
26
Aurexis®Bristol Myers SquibbPhase 2
35
Aurexis® (tefibazumab)Bristol Myers SquibbPhase 2
35
blood samples + nasal swabsSanofiPre-clinical
26
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIXBiotechPhase 1/2
22